Abstract
Objective To investigate trends and inequalities in statin use for the primary and secondary prevention of cardiovascular disease (CVD)
Design Repeated cross-sectional and historical cohort study designs
Setting English primary care electronic health records from the Clinical Practice Research Datalink (CPRD Aurum) linked to Hospital Episode Statistics Admitted Patient Care
Participants 5 million adults aged 25 years and older randomly sampled from CPRD Aurum between 1st April 2009 and 31st December 2021.
Outcome measures Monthly proportion of current statin users; adjusted odds ratios (aOR) for statin initiation; adjusted hazard ratios (aHR) for cardiovascular risk assessment, statin discontinuation and statin re-initiation and number of CVD events prevented with optimal statin use and estimated costs saved.
Results The overall monthly proportion of individuals prescribed statins for primary prevention increased from 22.3% in 2009 to 35.6% in 2021 among those aged 70+ years, and was stable in other age groups. The proportion of eligible individuals receiving a statin for secondary prevention was higher in all age groups (e.g. increasing from 68.1% to 73.7% over the same period, in those aged 70+). Overall prevalence of statin use was lowest among women, 25-39 age group, and black, mixed, and other ethnic groups for both primary and secondary prevention. Monthly proportion of CVD risk assessment, among those eligible, increased from 13.7% in May 2009 to 31.8% by November 2021. 79.0% of individuals were initiated statins within 60 days of a CVD event. Women (aOR 0.70; 95% CI, 0.68 − 0.72) and people of black ethnicity (aOR 0.71; 95% CI, 0.65-0.77) were less likely to be initiated statins compared to those of white ethnicity while people of south Asian ethnicity (aOR 1.53; 95% CI, 1.42-1.64) were more likely to be initiated statins than white people for secondary prevention. Statin discontinuation was most likely among women (aHR 1.08, 95% CI; 1.06−1.11) black people (aHR 1.76, 95% CI, 1.65−1.89) and the most deprived group (aHR 1.08, 95% CI; 1.04−1.12) compared to men, white people and the least deprived group, respectively, for primary prevention with similar associations seen for secondary prevention for ethnicity and deprivation. With optimal statin treatment, over 150,000 cardiovascular events could be prevented in the next 10 years for primary prevention and 5 years for secondary prevention resulting in a potential saving to the health service of over £400 million in those eligible for statins.
Conclusion Statin use remains suboptimal and inequalities particularly among women, people of black ethnicity and those in the most deprived socioeconomic groups persist across multiple stages of statin use for both primary and secondary prevention. To reduce these inequalities and avoid missed opportunities to prevent cardiovascular events and costs to the NHS, strategies are needed specifically targeting these patient groups to reduce the burden of CVD.
What is already known on this topic
Previous studies have shown that statins are under-prescribed and under-used in both primary and secondary prevention of cardiovascular disease (CVD) resulting in missed opportunities to reduce CVD burden.
Few studies have examined trends in statin use in recent years, including during the pandemic period.
Inequalities in statin use based on age, gender, ethnicity and deprivation have been identified previously, however it is unclear where, along the pathway from identification of eligible patients to initiation and continuation of statins, these inequalities manifest.
What this study adds
Levels of CVD risk assessment were suboptimal throughout the study period: a modest increase in the proportion of eligible individuals with a CVD risk assessment from 14% in May 2009 to 35% in February 2020 was followed by a decline during the COVID-19 pandemic.
Prevalence of statin use increased between 2009 and 2021 but remained suboptimal throughout, and with important sociodemographic disparities. Women and people of black ethnicity were less likely to initiate statins for secondary prevention compared to men and the white ethnic group while people of south Asian ethnicity and the 60-69 age group were more likely to initiate statins compared to people of white ethnicity and the 25-39 age group, respectively.
Statin discontinuation was higher among women than men (secondary prevention only), black ethnic groups compared to white ethnic groups, and the most deprived socioeconomic groups compared to the least deprived for both primary and secondary prevention.
We estimated that over 100,000 cardiovascular events could be prevented in the next 10 years if the observed missed opportunities for statin use in primary CVD prevention among eligible individuals were fully addressed, and a further 50,000 events could be prevented over 5 years for secondary prevention. The consequent potential saving to the health service was estimated to be over £400 million.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Protocols
https://github.com/RutendoMuzambi/trends_statin_use
Funding Statement
This study was funded by the British Heart Foundation (PG/19/71/34632).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Our study protocol was approved via CPRD Research Data Governance (RDG) process (study ID 22_001872). Ethical approval was also obtained from the London School of Hygiene and Tropical Medicine research ethics committee (reference: 28002)
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Data were obtained from the CPRD and are not publicly available. Access to CPRD data is dependent upon approval of a study protocol via CPRD RDG process (details at https://cprd.com/research-applications)
